$Johnson & Johnson(JNJ.US)$ $SINOPHARM(01099.HK)$ COVID-19 vaccines from U.S. drugmaker Johnson & Johnson and China's Sinopharm as well as Russia's Sputnik V shot had no neutralizing activity against the Omicron variant, according to a study which has not yet been peer reviewed.
The Omicron variant has raised concerns regarding its ability to evade protection provided by widely-used vaccines, with drugmakers tailoring their shots to target the variant while testing the effectiveness of their existing shots.
Vaccines from $Moderna(MRNA.US)$ , $ASTRAZENECA PLC(AZNCF.US)$ and $Pfizer(PFE.US)$ and partner $BioNTech(BNTX.US)$ retained activity against Omicron, but the antibody response was greatly reduced when compared with the original virus strain first detected in China, the study found.
The study also found that while the effectiveness of $GlaxoSmithKline(GSK.US)$ and Vir Biotech's COVID-19 drug sotrovimab reduced three-fold against Omicron compared to the original strain, monoclonal antibody treatments by Regeneron and Eli Lilly completely lost their neutralizing activity against the variant.
The finding is consistent with recent laboratory tests demonstrating the two treatments lose most of their effectiveness when exposed to the Omicron variant.

$Pfizer(PFE.US)$ $阿里那制药(ARNA.US)$ Buoyed by vaccine profits, Pfizer is clearly seizing the opportunity to put some money to work through diversified acquisitions. Pfizer buys Pharmaceutical rival Arena for $6.7 billion, sending shares up 90%. Arena's product portfolio includes multiple promising development stage drug candidates in gastroenterology, dermatology and cardiology. Arena also has two cardiovascular drugs in development, Temanogrel and APD418.

$Pfizer(PFE.US)$ which you think better invest. Moderna or J nJ.   you think Moderna not being able to do anything with o.icron gonna raise or lower. the other two seem to think they will basically help protect against new variant if understanding things rite. any input?????